We are analyzing https://link.springer.com/article/10.1007/s00198-004-1612-7.

Title:
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing | Osteoporosis International
Description:
Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced compliance by patients. The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommended animal models of human osteoporosis. These experimental studies of ibandronate indicate that the preclinical pharmacology and PK profile of ibandronate are broadly similar to those of other nitrogen-containing bisphosphonates. The efficacy of intermittent administration of subcutaneous (s.c.) and i.v. ibandronate has been demonstrated in four animal models (rat, dog, minipig, and monkey). Thus in rats, dogs, and monkeys with estrogen depletion, and in minipigs with glucocorticoid-induced bone loss, ibandronate administered s.c. or i.v. with extended intervals between doses reduces bone turnover, increases bone mineral density, and maintains bone quality in a dose-dependent manner. Furthermore, studies in rats and dogs comparing continuous and intermittent treatment schedules indicate similar efficacy when the same cumulative dose is applied over the duration of the study. These studies with ibandronate illustrate the concept that the total cumulative dose of bisphosphonate administered determines the response, independent of whether the dose is given daily or less frequently in a given time period. The efficacy of intermittent regimens has also been verified in models of secondary osteoporosis due to secondary hyperparathyroidism or immobilization (both in rats), or due to glucocorticoids in minipigs. Important factors for determining efficacy and the magnitude of response are the doses given, the length of the interval between doses, and the underlying bone turnover rate. The mechanisms underlying the remarkable efficacy of intermittent bisphosphonate dosing are not fully understood and further research is needed. Importantly, ibandronate is the only bisphosphonate so far proven to reduce the risk of vertebral fractures significantly with a between-dose interval >2 months, in a prospective clinical trial. Collectively, the preclinical studies on ibandronate have provided a sound basis for the design of the convenient regimens currently being examined in clinical trials.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

bone, google, scholar, ibandronate, pubmed, cas, osteoporosis, article, bauss, bisphosphonate, int, miner, res, postmenopausal, suppl, treatment, intermittent, abstract, bisphosphonates, rats, study, preclinical, intravenous, osteoporos, administration, loss, dosing, alendronate, research, rat, daily, oral, efficacy, press, ovariectomized, russell, clinical, studies, dogs, mineral, density, quality, dose, tissue, recker, evaluation, model, review, women, calcif,

Topics {✒️}

gov/cder/foi/nda/98/20835_actonel gov/cder/foi/nda/2001/21-233_zometa month download article/chapter testosterone-stimulated vascular regrowth monier-faugere mc parathyroid hormone-related protein pharmacy record-based study glucocorticoid-induced bone loss national osteoporosis foundation established corticosteroid-induced osteoporosis unique drug-free interval intravenous bolus injection potent anti-osteolytic bisphosphonate long-term protective effect full-grown beagle dogs full article pdf monthly intravenous ibandronate bone mineral density carstens jh jr oral monthly ibandronate vertebral fractures significantly health maintenance organization privacy choices/manage cookies intravenous ibandronate injections botnar research centre intermittent ibandronate injections cost-effectiveness analysis van de ruit chesnut iii ch prevents hyperparathyroid bone prevent bone loss disuse bone loss mineral binding affinities long-term infusion long-term study 6 mg iv administration pharma research penzberg proprietary medicinal products ayd fj jr intermittent oral ibandronate mf4265 study group intermittent bisphosphonate dosing orthop res soc intravenous zoledronic acid dosing intravenous administration malignant bone diseases cortical bone loss intermittent intravenous administration ibandronate preserves bone weekly study group

Questions {❓}

Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
         description:Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced compliance by patients. The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommended animal models of human osteoporosis. These experimental studies of ibandronate indicate that the preclinical pharmacology and PK profile of ibandronate are broadly similar to those of other nitrogen-containing bisphosphonates. The efficacy of intermittent administration of subcutaneous (s.c.) and i.v. ibandronate has been demonstrated in four animal models (rat, dog, minipig, and monkey). Thus in rats, dogs, and monkeys with estrogen depletion, and in minipigs with glucocorticoid-induced bone loss, ibandronate administered s.c. or i.v. with extended intervals between doses reduces bone turnover, increases bone mineral density, and maintains bone quality in a dose-dependent manner. Furthermore, studies in rats and dogs comparing continuous and intermittent treatment schedules indicate similar efficacy when the same cumulative dose is applied over the duration of the study. These studies with ibandronate illustrate the concept that the total cumulative dose of bisphosphonate administered determines the response, independent of whether the dose is given daily or less frequently in a given time period. The efficacy of intermittent regimens has also been verified in models of secondary osteoporosis due to secondary hyperparathyroidism or immobilization (both in rats), or due to glucocorticoids in minipigs. Important factors for determining efficacy and the magnitude of response are the doses given, the length of the interval between doses, and the underlying bone turnover rate. The mechanisms underlying the remarkable efficacy of intermittent bisphosphonate dosing are not fully understood and further research is needed. Importantly, ibandronate is the only bisphosphonate so far proven to reduce the risk of vertebral fractures significantly with a between-dose interval >2 months, in a prospective clinical trial. Collectively, the preclinical studies on ibandronate have provided a sound basis for the design of the convenient regimens currently being examined in clinical trials.
         datePublished:2004-03-26T00:00:00Z
         dateModified:2004-03-26T00:00:00Z
         pageStart:423
         pageEnd:433
         sameAs:https://doi.org/10.1007/s00198-004-1612-7
         keywords:
            Bisphosphonate
            Ibandronate
            Intermittent
            Osteoporosis
            Preclinical
            Orthopedics
            Endocrinology
            Rheumatology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7flb1.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7fhc2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7flb3.gif
         isPartOf:
            name:Osteoporosis International
            issn:
               1433-2965
               0937-941X
            volumeNumber:15
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Frieder Bauss
               affiliation:
                     name:Pharma Research Penzberg
                     address:
                        name:Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:R. Graham G. Russell
               affiliation:
                     name:Nuffield Orthopaedic Centre
                     address:
                        name:The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing
      description:Ibandronate is a highly potent, nitrogen-containing bisphosphonate. Unlike most other bisphosphonates, it is under clinical development for both oral and intravenous (i.v.) administration. Ibandronate can be used in convenient intermittent regimens that may optimize therapeutic outcome with enhanced compliance by patients. The preclinical pharmacokinetics (PK) and pharmacology of ibandronate have been extensively explored in a large preclinical development program involving various recommended animal models of human osteoporosis. These experimental studies of ibandronate indicate that the preclinical pharmacology and PK profile of ibandronate are broadly similar to those of other nitrogen-containing bisphosphonates. The efficacy of intermittent administration of subcutaneous (s.c.) and i.v. ibandronate has been demonstrated in four animal models (rat, dog, minipig, and monkey). Thus in rats, dogs, and monkeys with estrogen depletion, and in minipigs with glucocorticoid-induced bone loss, ibandronate administered s.c. or i.v. with extended intervals between doses reduces bone turnover, increases bone mineral density, and maintains bone quality in a dose-dependent manner. Furthermore, studies in rats and dogs comparing continuous and intermittent treatment schedules indicate similar efficacy when the same cumulative dose is applied over the duration of the study. These studies with ibandronate illustrate the concept that the total cumulative dose of bisphosphonate administered determines the response, independent of whether the dose is given daily or less frequently in a given time period. The efficacy of intermittent regimens has also been verified in models of secondary osteoporosis due to secondary hyperparathyroidism or immobilization (both in rats), or due to glucocorticoids in minipigs. Important factors for determining efficacy and the magnitude of response are the doses given, the length of the interval between doses, and the underlying bone turnover rate. The mechanisms underlying the remarkable efficacy of intermittent bisphosphonate dosing are not fully understood and further research is needed. Importantly, ibandronate is the only bisphosphonate so far proven to reduce the risk of vertebral fractures significantly with a between-dose interval >2 months, in a prospective clinical trial. Collectively, the preclinical studies on ibandronate have provided a sound basis for the design of the convenient regimens currently being examined in clinical trials.
      datePublished:2004-03-26T00:00:00Z
      dateModified:2004-03-26T00:00:00Z
      pageStart:423
      pageEnd:433
      sameAs:https://doi.org/10.1007/s00198-004-1612-7
      keywords:
         Bisphosphonate
         Ibandronate
         Intermittent
         Osteoporosis
         Preclinical
         Orthopedics
         Endocrinology
         Rheumatology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7flb1.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7fhc2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00198-004-1612-7/MediaObjects/s00198-004-1612-7flb3.gif
      isPartOf:
         name:Osteoporosis International
         issn:
            1433-2965
            0937-941X
         volumeNumber:15
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Frieder Bauss
            affiliation:
                  name:Pharma Research Penzberg
                  address:
                     name:Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:R. Graham G. Russell
            affiliation:
                  name:Nuffield Orthopaedic Centre
                  address:
                     name:The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Osteoporosis International
      issn:
         1433-2965
         0937-941X
      volumeNumber:15
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Pharma Research Penzberg
      address:
         name:Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
         type:PostalAddress
      name:Nuffield Orthopaedic Centre
      address:
         name:The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Frieder Bauss
      affiliation:
            name:Pharma Research Penzberg
            address:
               name:Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:R. Graham G. Russell
      affiliation:
            name:Nuffield Orthopaedic Centre
            address:
               name:The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Roche Diagnostics, Pharma Research Penzberg, Penzberg, Germany
      name:The Botnar Research Centre and Oxford University Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Oxford, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(165)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

3.89s.

LINK . SPRINGER . COM {}